Principal Investigator
Carl Landgren
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20221148
Clinical Trial Summary
Teclistamab or Talquetamab in Combination with Daratumumab SC for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Sequential Cohort Immuno-oncology Study to REVIVE Early Myeloma
Phase
Phase II
Funding Agency/Sponsor
Institutional
Disease
Myeloma
Contact Information
Phone Number
305-243-2647